0001346302-21-000076 | 10-Q | XBRL Viewer | Xeris Pharmaceuticals INC

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statements of Operations [Abstract]
Grant and other income	$ 71	$ 41	$ 215	$ 153

Label	Element	Value
AccrualForRebatesAndTradeDiscounts	xers_AccrualForRebatesAndTradeDiscounts	$ 6,799,000
AccrualForRebatesAndTradeDiscounts	xers_AccrualForRebatesAndTradeDiscounts	$ 5,984,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled upon Option exchange	xers_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledUponOptionExchange	1,127,906
Payments Related To Tax Withholding For Share Based Compensation, RSUs	xers_PaymentsRelatedToTaxWithholdingForShareBasedCompensationRSUs	$ 63,000
Payments Related To Tax Withholding For Share Based Compensation, RSUs	xers_PaymentsRelatedToTaxWithholdingForShareBasedCompensationRSUs	63,000
Payments Related To Tax Withholding For Share Based Compensation, RSUs	xers_PaymentsRelatedToTaxWithholdingForShareBasedCompensationRSUs	365,000
Payments Related To Tax Withholding For Share Based Compensation, RSUs	xers_PaymentsRelatedToTaxWithholdingForShareBasedCompensationRSUs	365,000
Unrecognized expense from restricted stock units	xers_Unrecognizedexpensefromrestrictedstockunits	8,800,000
Increase in accrued returns reserve	xers_Increaseinaccruedreturnsreserve	412,000
Increase in accrued returns reserve	xers_Increaseinaccruedreturnsreserve	520,000
Final payment fee settled at closing	xers_FinalPaymentFeeSettledAtClosing	$ 600,000
Initial conversion rate for Convertible Notes	xers_InitialConversionRateForConvertibleNotes	326.7974
Initial conversion rate for Convertible Notes	xers_InitialConversionRateForConvertibleNotes	326.7974
Common shares issued, due to exercise of underwriter option	xers_Commonsharesissuedduetoexerciseofunderwriteroption	1,299,769
Common shares issued, due to exercise of underwriter option	xers_Commonsharesissuedduetoexerciseofunderwriteroption	1,110,000
Accrued returns reserve	xers_Accruedreturnsreserve	$ 3,301,000
Accrued returns reserve	xers_Accruedreturnsreserve	2,889,000
Net proceeds from issuance of public offering	xers_Netproceedsfromissuanceofpublicoffering	39,900,000
Net proceeds from issuance of public offering	xers_Netproceedsfromissuanceofpublicoffering	21,600,000
Net proceeds from issuance of public offering	xers_Netproceedsfromissuanceofpublicoffering	26,900,000
Prepayment fee settled at closing	xers_PrepaymentFeeSettledAtClosing	300,000
Statutory withholding taxes on vesting and settlement of RSUs	xers_StatutoryWithholdingTaxesOnVestingAndSettlementOfRSUs	400,000
Statutory withholding taxes on vesting and settlement of RSUs	xers_StatutoryWithholdingTaxesOnVestingAndSettlementOfRSUs	100,000
Per principal amount of Convertible Notes	xers_PerPrincipalAmountOfConvertibleNotes	1,000
Per principal amount of Convertible Notes	xers_PerPrincipalAmountOfConvertibleNotes	1,000
Accrued trade discounts and rebates	xers_Accruedtradediscountsandrebates	815,000
Accrued trade discounts and rebates	xers_Accruedtradediscountsandrebates	1,037,000
Common stock value, tax limit on employee stock purchase plan	xers_Commonstockvaluetaxlimitonemployeestockpurchaseplan	$ 25,000
Available For Sale Securities Maturities Period	xers_AvailableForSaleSecuritiesMaturitiesPeriod	3 months 18 days
Minimum cash balance to be held with lender	xers_MinimumCashBalanceToBeHeldWithLender	$ 5,000,000.0
Maximum conversion rate of Convertible Notes	xers_MaximumConversionRateOfConvertibleNotes	367.6470
Amendment fee to be settled at maturity	xers_AmendmentFeeToBeSettledAtMaturity	$ 100,000
Class of warrants, expired	xers_ClassOfWarrantsExpired	1,419
Least amount of annual increase of shares available for issuance	xers_Leastamountofannualincreaseofsharesavailableforissuance	386,000
Prepayment allowed per debt agreement	xers_Prepaymentallowedperdebtagreement	$ 2,000,000.0
Principal amount of convertible notes converted	xers_PrincipalAmountOfConvertibleNotesConverted	$ 8,400,000
Total common stock and preferred stock authorized shares	xers_TotalCommonStockAndPreferredStockAuthorizedShares	160,000,000.0
Stock Issued During Period, Shares, Vesting Of Restricted Stock Units	xers_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits	21,449
Stock Issued During Period, Shares, Vesting Of Restricted Stock Units	xers_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits	148,643
Accrued research costs	xers_Accruedresearchcosts	$ 1,027,000
Accrued research costs	xers_Accruedresearchcosts	678,000
Accrued supply chain costs	xers_AccruedSupplyChainCosts	731,000
Accrued supply chain costs	xers_AccruedSupplyChainCosts	$ 1,702,000
Restricted stock units vested and settled during period	xers_RestrictedStockUnitsVestedAndSettledDuringPeriod	220,425
Restricted stock units vested and settled during period	xers_RestrictedStockUnitsVestedAndSettledDuringPeriod	31,250
Class of warrants, exercised	xers_Classofwarrantsexercised	18,512
Principal amount of convertible notes converted privately	xers_PrincipalAmountOfConvertibleNotesConvertedPrivately	$ 30,700,000
Accrued Transaction Costs, Current	xers_AccruedTransactionCostsCurrent	2,930,000
Accrued Transaction Costs, Current	xers_AccruedTransactionCostsCurrent	$ 0
Preferred stock and warrants issued during the period, shares	xers_Preferredstockandwarrantsissuedduringtheperiodshares	19,931
Preferred stock and warrants issued during the period, shares	xers_Preferredstockandwarrantsissuedduringtheperiodshares	53,720
Preferred stock and warrants issued during the period, shares	xers_Preferredstockandwarrantsissuedduringtheperiodshares	40,292
Stock Issued During Period, Shares, Conversion of Convertible Securities privately exchanged	xers_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPrivatelyExchanged	10,435,200
Loss on the convertible note exchange transactions	xers_LossOnTheConvertibleNoteExchangeTransactions	$ 2,600,000
Convertible notes purchased, due to exercise of underwriter option	xers_ConvertibleNotesPurchasedDueToExerciseOfUnderwriterOption	$ 11,300,000
Share-based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period upon Option Exchange	xers_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodUponOptionExchange	832,907

Print Document View Excel Document
Financial Statements Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Uncategorized Uncategorized Items - xers-20210630_htm.xml All Reports